BioNTech SE - ESG Rating & Company Profile powered by AI
The Disclosure rating covers 17 United Nations Sustainable Development Goals including: 'Quality Education', 'Reduced Inequalities' and 'Life below Water'. Scroll down to the bottom of this webpage for potential risks for BioNTech SE based on sector, location and marketcap. This page includes a questions and answers table on BioNTech SE.
BioNTech SE in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 2.3, social score of 4.6 and governance score of 8.0.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 912 | Vivanza Biosciences Ltd | 5.3 | High |
| 912 | ValiRx PLC | 5.3 | High |
| 958 | BioNTech SE | 5.2 | High |
| 958 | Altimmune Inc | 5.2 | High |
| 958 | Agios Pharmaceuticals Inc | 5.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does BioNTech SE have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes BioNTech SE disclose current and historical energy intensity?
Sign up for free to unlockDoes BioNTech SE report the average age of the workforce?
Sign up for free to unlockDoes BioNTech SE reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes BioNTech SE disclose its ethnicity pay gap?
Sign up for free to unlockDoes BioNTech SE disclose cybersecurity risks?
Sign up for free to unlockDoes BioNTech SE offer flexible work?
Sign up for free to unlockDoes BioNTech SE have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes BioNTech SE disclose the number of employees in R&D functions?
Sign up for free to unlockDoes BioNTech SE conduct supply chain audits?
Sign up for free to unlockDoes BioNTech SE disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes BioNTech SE conduct 360 degree staff reviews?
Sign up for free to unlockDoes BioNTech SE disclose the individual responsible for D&I?
Sign up for free to unlockDoes BioNTech SE disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes BioNTech SE disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes BioNTech SE disclose water use targets?
Sign up for free to unlockDoes BioNTech SE have careers partnerships with academic institutions?
Sign up for free to unlockDid BioNTech SE have a product recall in the last two years?
Sign up for free to unlockDoes BioNTech SE disclose incidents of discrimination?
Sign up for free to unlockDoes BioNTech SE allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas BioNTech SE issued a profit warning in the past 24 months?
Sign up for free to unlockDoes BioNTech SE disclose parental leave metrics?
Sign up for free to unlockDoes BioNTech SE disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes BioNTech SE disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes BioNTech SE disclose the pay ratio of women to men?
Sign up for free to unlockDoes BioNTech SE support suppliers with sustainability related research and development?
Sign up for free to unlockDoes BioNTech SE disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes BioNTech SE reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs BioNTech SE involved in embryonic stem cell research?
Sign up for free to unlockDoes BioNTech SE disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes BioNTech SE disclose its waste policy?
Sign up for free to unlockDoes BioNTech SE report according to TCFD requirements?
Sign up for free to unlockDoes BioNTech SE disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes BioNTech SE disclose energy use targets?
Sign up for free to unlockDoes BioNTech SE disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes BioNTech SE have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for BioNTech SE
These potential risks are based on the size, segment and geographies of the company.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.